Gemin X Pharmaceuticals has closed an $8 million Series E round of funding that it will use to prepare for Phase 3 clinical trials of its lung cancer drug.
The Malvern, Pennsylvania-based company is in the midst of a Phase 2b trial of its lead candidate, obatoclax, which is intended for the treatment of extensive-stage small-cell lung cancer. Small-cell lung cancer is considered “extensive-stage” if it’s spread from one lung to other parts of the body, such as the liver or brain.
Small-cell lung cancer accounts for about 15 percent of lung cancer, according to the National Cancer Institute.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s unclear when Gemin X will begin its Phase 3 trial, but it’s safe to say it won’t happen this year, a company spokeswoman said.
Gemin X’s latest fundraise brings the total amount of equity it’s brought in to $120 million since the company was founded in 1998, the spokeswoman said. The Series E round was led by Caxton Advantage Life Sciences Fund and Sanderling Venture Partners.
Aside from obatoclax, Gemin X has several other cancer-fighting drugs in its pipeline.